Member Info for dactions

Interesting thoughts re the cannabinoid market - I hadn't realised Futura were involved. Now that would be some really good news if they indeed are and have made good progress on it. The AIM market is quite frothy right now - it doesn't take much speculation to get a share going but I'd rather have some tangible comments from Barder.

If possible please Mr Barder ?

Helen - thank you for the document.
One extract I found interesting was in the appendix relating to Synairgen's good safety record as detailed below - also of significance it that trial participants will be in the program for almost 6 months.

HOW LONG WILL I BE IN THIS STUDY?
If you are assigned to SGN001 or placebo for SGN001, you will be in this study for 24
weeks.
WHAT ARE THE RISKS OF SNG001?
There is a risk of serious and/or life-threatening side effects when non-study medications
are taken with the study drugs. For your safety, you must tell the study doctor or nurse
about all medications you are taking before you start the study.
Another risk is that the study drug used in this study may have side effects, some of which
are listed below. Additionally, the study drug tested in the study may have unknown side
effects in persons with SARS-CoV-2 infection. In a research study, all of the risks or side
effects may not be known before you start the study. You need to tell your doctor or a
member of the study team immediately if you experience any side effects.
Please note that these lists do not include all the side effects seen with this study drug.
These lists include the more serious or common side effects with a known or possible
relationship to the study drug. If you have questions concerning the additional side effects,
please ask the medical staff at your site.
Risks Associated with Inhaled SNG001
There is limited safety data on inhaled SNG001 since it has not been given to a lot of
people. This study will be one of the first studies to give inhaled SNG001 to nonhospitalized
patients with COVID-19. A study of inhaled SNG001 in COVID-19 outpatients
was recently started in the UK. As of December 4, 2020, there have been no serious
unwanted effects reported by >300 healthy people and patients with asthma, as well as 100
COVID-19 patients, taking inhaled SNG001. Most effects after taking inhaled SNG001 or
placebo for SNG001 have been mild or moderate and have either all gone away or are
getting better.
Based on previous trials, administration of inhaled SNG001 may result in
• Fast heart rate
• Coughing
• Deposits of drug product on the top and back of mouth and throat
• Dry throat
• Hoarseness of voice
• Sneezing
• Tremors
• Headache
There is extensive experience from individuals who have received intravenous injections of
IFN-ß-1, as this is has been approved for treatment of multiple sclerosis in the United
States since 1996. The most common side effects from intravenous injections of IFN-ß-1
are mild and short-lived, including flu-like symptoms such as headache, fever, muscle
aches, and chills. Rare side effects that have been reported from intravenous injections of
IFN-ß-1 include severe allergic reactions, low white blood cell counts, liver injury, kidney
injury, seizures, depression, and suicidal thoughts. EndQuote

Thanks Owl11

From the California Journal published yesterday:
“We’re on the lookout for therapeutics to help people who aren’t sick enough to go to the hospital, which is the vast majority of people who get COVID,” said Prasanna Jagannathan, infectious disease specialist at Stanford Medicine and assistant professor of microbiology and immunology.
Among those in the pipeline is Synairgen’s SNG001, an inhalable beta interferon. This type of drug helps reduce inflammation and the body’s immune reaction.

Jagannathan, from Stanford, is one of the lead investigators on interferon, and he likes what he sees.

“We’re really excited about this for a couple of reasons,” he said. “Interferon seems to play a really important role in the body’s early response to infection. There’s evidence that people with deficient signaling go on to have more severe disease, and early evidence suggests that giving this particular interferon could be beneficial.”

Hi Notmuchinsales - I really appreciate you having checked this out with CG. As a LTH, I'm not at all happy the way he has run this and having spoken with him on a 1 to 1 several times over the years I felt he was genuine in his responses but could have done with more help along the way.

As TruroTrader says, he's stuck at it and I would add that in my opinion CG should be able to turn this around with or without the snatched quarry. Kosovo doesn't want to be an European backwater and I reckon they'll settle this dispute to our advantage. How much I can't say but it will impact the sp in a decent fashion from the silly level of 2p right now.

Sorry - I keep spelling his name wrong.
He's worth following on twitter and is very knowledgeable on Covid - at Amiens Hospital where Sng is being trialled under Phase III - Clinical Pharmacist Aurélien Mary

Synairgen is based on IFN-ß-1a as opposed to 1b that is the Extavia product.
JoeyDiamond gives a good explanation of the differences.

Synairgen is also given by injection to MS sufferers but the treatment trial a few years ago, was refused to MS sufferers above aged 60 and as far as I'm aware that age limit was never removed. My Wife has MS and we understand that in the UK users are on 1a - and there has been no mention in her large South-East MS group of the name of Extavia.

Our Clinical Pharmacist Aurleian MARY is based in Amiens, France and is well aware of Synairgen and unless I'm completely biased (quite possible) he believes in the merits of Synairgen as he was one of those to seek trials last Spring at his hospital. But in fairness I do recall he was excited by the chance to test Interferon Beta 1b - which I believe is under test in Bordeaux but, as I say, he is positive towards SNG and if it came down to price, that would be something RM could easily solve so overall I look on the French news today very positively.

Brainspark - what's the tip please - do you have a link ?

Cheers oldtramp - yes the article shows the possible promise in this market segment.

Adastra - I like your positive write-ups - perhaps TPG should be hiring you for their press-relations. Ooh - there's a thought - perhaps they have ;-)

What to make of today's rise - clawing back some of Monday's fall & getting near to the high point of last Friday - when most stocks were in the red today ? Surely, there has to be some positive tangible news coming ?

After the Proactiveinvestors interview with James Barder in late October, when in my eyes he looked like a man who was desperate to 'tell all', I was convinced we'd hear something positive pre-Christmas - now all these many months later and not a peep !

So much for my reading of body language - what do I know ?

Happyinvestor - I don't get it why you want to post stuff like :
"The only wave coming is the one that is about to drown SNG investors...."

You've been a poster on lse for best part of a year running up over a 1000 posts - you know what these BBs are for - to exchange views in support or if you don't hold shares, to raise points that worry you about investing in that Co's shares - not as you're doing to **** off fellow investors.

A couple of late published trades went through today 1 of 1 million + shares and another of approx 750,000 along with a whole host a small to medium sized ones including my own one. All showing as ‘Undisclosed ‘ - but will have been BUYS.

Could litigation news be soon ?

oldtramp - really interesting read on the science - thanks

Although it reminded me that CJB Developments Ltd was bought by Phil Cartmell (TPG - then Corac) in 2012 with a placing of 10.5p raising £6.5 millions and he said at the time:

Commenting, Phil Cartmell, Executive Chairman said:
“We believe this acquisition will bring strong strategic and financial benefits for Corac as it represents an opportunity to acquire long established, niche profitable businesses with complementary technology and expertise.”
“We believe this will further strengthen the Corac proposition for our partners, customers and investors. It will transform Corac into a technology-led engineering group serving major global industries with established commercial relationships and a track record of revenue and profit contribution.”

We're still waiting to see the profit on that one !

Oldbaldy - getting some juvenile comments here today - best to filter them

Added more today - trying to lower my buying average.

All those deals this morning at 2p are BUYS.
I wonder if they're Brandon Hill shares supposedly sold off at 1.6p to fund in part the litigation - I guess so ?

Oh well, paid .4p extra - what's new with my dealings with FOX.
If so, it's gone to a good cause this time and I'm hoping for a positive or even half-positive outcome which I am expecting will lift the sp.

Trying to be realistic - I'm looking for 5p by the Summer.

NickyP - of course you're right - I completely forgot the historic Miles Pelham connection - I wonder what he makes of the focused change in direction by the new Board ?

The RNS today from Canadian Venture Capitalists, Rhino Venture says that they've converted 100 million of non-voting shares to voting shares and disposed of them. In turn we learn that Sparta Premier based in British Virgin Islands is the new share owner of the new voting shares.

What's interesting, or perhaps typical of the AIM shares market, is that information clearly leaked and lies behind the big market share purchases in recent days mentioned earlier in this thread.

Still, overall, it's very good news for all us share holders - showing that others see Woodbois as an attractive share holding.

Long may that continue - good luck all.

Cheers Radius - that explains it

I sold out at 2.5p and said I was hoping to get back in when I had assumed it would fall back nearer the placing of 1.75p. That hasn't happened perhaps largely because of TW's tip in his *otstockrockets.

So, I got that wrong - but I would just add though some caution not to chase this, as at the moment we have yet to see what market share they're getting.
Good luck all.

I don't think the gauge has anything to do with it as the bulk of Europe and us included has been on a common gauge for some time.

I'm pleased to see some sp rise though although I'd have liked to seen a better RNS frankly - with something more tangible in it.

Notmuchinsales - you are definitely right about Fox 's sales efforts - I don't disagree with you at all.

I paid as much as 25p for some of my FOX shares - I think it was when the chartist, Zak Mir said they were about to break out markedly upwards - he couldn't have been more wrong as I found to my cost - I've discarded his comments ever since which is probably unfair. As for Fox's turnover, I've likened it in the past to that of a local Garden Centre I know well and there they don't have to do anything risky and enjoy steady increases in Turnover and even better increases in overall profitability.

Back to Fox, the difference is that now, at these low sp levels, there's a fair chance of a multi-bagger, although an element of luck will be involved, but I reckon there's a good chance of doing well out of the current litigation. And perhaps, just perhaps, a chance Fox will get round to selling some decent sized Marble contracts as well !